Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Top Page
Anavex Life Sciences
(NASDAQ:AVXL)
Rating:62Neutral
Price Target:―
Positive Factors
Clinical Trials
The successful completion of enrollment in the Phase 2 clinical study for ANAVEX3-71 signals progress in developing a treatment for schizophrenia.
Market Opportunity
Possible blarcamesine EU market entry could make the European market opportunity highly lucrative.
Regulatory Approval
Positive commentary from the European Medicines Agency could have a huge upside to the stock and indicate success with other ex-US regulatory bodies.
Negative Factors
Partnerships
The company is exploring partnership options, but no concrete deals have been announced at this time.
Regulatory Challenges
The uncertainty around approval in the U.S. and lack of any ex-US partnership news are the key holdups for the stock.
Regulatory Requirements
The FDA will likely require the company to run a larger Phase 3 study prior to an NDA submission.
Anavex Life Sciences (AVXL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$810.84M
Dividend YieldN/A
Average Volume (3M)1.11M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS Growth-13.05%
CountryUS
Employees42
SectorHealthcare
Sector Strength53
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding85,893,840
10 Day Avg. Volume993,254
30 Day Avg. Volume1,108,642
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.63
Forecast
1Y Price Target
$42.00Price Target Upside339.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anavex Life Sciences Business Overview & Revenue Model
Company DescriptionAnavex Life Sciences Corp. is a clinical-stage biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases. The company is primarily focused on developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative and neurodevelopmental disorders. Anavex's lead compound, ANAVEX2-73 (blarcamesine), is being studied for its potential to modify disease progression and improve symptoms in these conditions.
How the Company Makes MoneyAnavex Life Sciences makes money primarily through the development and commercialization of its drug candidates. The company's revenue model hinges on successfully advancing its drug pipeline through clinical trials and obtaining regulatory approvals. Once approved, Anavex can generate revenue through the sale of its drugs to healthcare providers and patients. Additionally, the company may enter into partnerships or licensing agreements with larger pharmaceutical companies to co-develop or market its compounds, which can provide upfront payments, milestone payments, and royalties from sales. However, as a clinical-stage company, Anavex may not yet have significant revenue from product sales until its drugs are approved and commercially available.
Anavex Life Sciences Earnings Call Summary
Earnings Call Date:Aug 12, 2025
(Q3-2025)
| % Change Since: -15.86%|
Next Earnings Date:Dec 22, 2025
Earnings Call Sentiment Neutral
The earnings call presents a balanced view with strong ongoing development and financial health, but also challenges in administrative costs and net losses. The company's advancements in Alzheimer's treatment and cash flow are positive, but operational costs and delays in Parkinson's study present concerns.Q3-2025 Updates
Positive Updates
Continued Benefit of Blarcamesine in Alzheimer's
Open-label extension data demonstrated clinically meaningful benefits in early-stage Alzheimer's patients, with benefits accruing over 4 years.
Strong Cash Position
Anavex reported a cash position of $101.2 million with no debt, and an estimated runway of more than 3 years.
Reduced R&D Expenses
Research and development expenses decreased to $10 million from $11.8 million in the comparable quarter last year.
Potential Market Penetration
Oral therapies like blarcamesine are seen as more accessible and potentially requiring less complex administration compared to injectable monoclonal antibodies, indicating potential for broader market penetration.
Negative Updates
Increased General and Administrative Expenses
General and administrative expenses rose to $4.5 million from $2.8 million in the comparable quarter of last year.
Net Loss
Reported a net loss of $13.2 million for the quarter or $0.16 per share.
Delayed Start of Parkinson's Study
The next Parkinson's study is delayed due to dynamic shifts in understanding of the disease and challenges with L-dopa.
Company Guidance
During the Anavex Life Sciences Fiscal 2025 Third Quarter Conference Call, significant guidance was provided, including clinical and financial updates. The company presented data from the Alzheimer's Association International Conference 2025, showcasing their promising drug blarcamesine, which demonstrated sustained benefits in early-stage Alzheimer's patients over four years, measured by ADAS-Cog13 and ADCS-ADL endpoints. Financially, Anavex reported a cash position of $101.2 million as of June 30, 2025, with no debt, and a net loss of $13.2 million for the quarter, equating to $0.16 per share. The company emphasized an adjusted cash utilization rate offering a projected runway of more than three years. Additionally, research and development expenses totaled $10 million, a decrease from the previous year's $11.8 million, while general and administrative expenses increased to $4.5 million compared to $2.8 million last year. The company also discussed ongoing preparations for future trials and potential commercialization strategies in Europe, highlighting a focus on penetrating markets with oral therapies to meet unmet needs in Alzheimer's care.Anavex Life Sciences Financial Statement Overview
Summary
Anavex Life Sciences shows a typical early-stage biotechnology financial profile with no revenue and consistent net losses. However, the balance sheet is strong with no debt, and the company has a good cash position. The financial sustainability depends heavily on future revenue generation from its biotech projects.Income Statement
Anavex Life Sciences has reported zero revenue over the analyzed periods, which is typical for early-stage biotechnology companies that are in the R&D phase. The company experiences consistent net losses, with a TTM net income of -$46.49 million. This indicates a high level of ongoing investment in research without current revenue generation, which is a significant risk factor for financial sustainability.25
Negative
Balance Sheet
The company's balance sheet shows a strong equity position with no debt, resulting in a debt-to-equity ratio of 0. This is a positive indicator of financial stability. However, the return on equity is negative due to ongoing net losses. The equity ratio remains solid, indicating that the company is predominantly financed by equity rather than liabilities.70
Positive
Cash Flow
Anavex Life Sciences demonstrates a negative operating cash flow, reflecting its pre-revenue stage. However, the company has maintained a healthy cash position and has managed to secure financing without taking on debt. The absence of revenue and free cash flow growth underscores the company's reliance on external financing for its operations.60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -71.20M | -45.29M | -55.76M | -50.94M | -37.38M | -30.63M |
| Net Income | -34.93M | -43.00M | -47.51M | -47.98M | -37.91M | -26.28M |
Balance Sheet | ||||||
| Total Assets | 102.43M | 135.57M | 154.39M | 152.70M | 161.62M | 34.54M |
| Cash, Cash Equivalents and Short-Term Investments | 101.16M | 132.19M | 151.02M | 149.16M | 152.11M | 29.25M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.47M | 15.30M | 12.53M | 10.21M | 10.80M | 7.31M |
| Stockholders Equity | 90.96M | 120.26M | 141.85M | 142.49M | 150.82M | 27.24M |
Cash Flow | ||||||
| Free Cash Flow | -37.10M | -30.81M | -27.79M | -24.24M | -30.38M | -21.29M |
| Operating Cash Flow | -37.10M | -30.81M | -27.79M | -24.24M | -30.38M | -21.29M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -494.00K | 11.97M | 29.65M | 21.29M | 153.24M | 28.35M |
Anavex Life Sciences Technical Analysis
Negative
9.55
Price Trends
10.39
Negative
9.41
Positive
9.32
Positive
Market Momentum
-0.29
Positive
37.88
Neutral
11.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVXL, the sentiment is Negative. The current price of 9.55 is below the 20-day moving average (MA) of 10.74, below the 50-day MA of 10.39, and above the 200-day MA of 9.32, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 37.88 is Neutral, neither overbought nor oversold. The STOCH value of 11.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVXL.
Anavex Life Sciences Risk Analysis
Anavex Life Sciences disclosed 52 risk factors in its most recent earnings report. Anavex Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anavex Life Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $810.84M | ― | -43.63% | ― | ― | -13.05% | |
61 Neutral | €1.88B | 22.07 | 12.16% | 2.07% | 7.83% | 13.92% | |
54 Neutral | $1.28B | ― | -15.64% | ― | -0.54% | -6.28% | |
51 Neutral | $605.68M | ― | -46.22% | ― | -75.91% | -12.11% | |
50 Neutral | $698.59M | ― | -24.75% | ― | 2190.50% | 52.85% | |
48 Neutral | $628.02M | ― | -32.71% | ― | ― | ― | |
43 Neutral | $752.26M | ― | -50.67% | ― | 41.86% | 10.48% |
* Healthcare Sector Average
Performance Comparison
AVXL
Anavex Life Sciences
9.55
3.23
51.11%
VIR
Vir Biotechnology
4.38
-4.39
-50.06%
NRIX
Nurix Therapeutics
9.65
-14.37
-59.83%
ABCL
AbCellera Biologics
4.30
1.69
64.75%
DAWN
Day One Biopharmaceuticals
6.98
-7.11
-50.46%
BCAX
Bicara Therapeutics Inc.
11.63
-13.78
-54.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.